Utilizing Autologous Multipotent Mesenchymal Stromal Cells and -Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial
Table 2
(a) Results of patients in the trial group. (b) Results of patients in the control group.
(a)
Case
1
12
1
0
0
1
1
3
2
12
1
0
0
1
1
3
3
12
1
0
0
1
1
3
4
12
1
0
0
3
2
3, 4
5
12
2
1
0
1
1
3, 4
6
12
2
0
1
4
1
3
7
12
1
0
0
1
1
3
8
12
1
0
0
1
1
3
9
12
2
0
0
0
1
3
(b)
Case
1
12
1
0
0
0
0
1
2
12
2
0
0
0
0
1
3
12
3
1
0
0
0
3
4
12
1
0
0
0
1
2
5
12
2
0
0
0
0
2
6
12
1
0
2
0
0
2
7
12
2
0
0
0
0
2
8
12
1
0
0
3
3
1, 4
9
12
1
0
0
0
0
1
: follow-up (months); : preoperative Harris Hip Score ± postoperative (points); : preoperative pain score ± the postoperative increase (points); : Trendelenburg sign: 1: preoperative positive and postoperative negative, 2: preoperative positive and postoperative positive, and 3: preoperative negative and postoperative negative; : orthopaedic complications: 0: none and 1: dislocation; : other complications: 0: none, 1: pulmonary embolism, and 2: cardiac arrhythmia; : heterotopic ossification preoperatively: 0: none, 1: grade I, 3: grade III, and 4: grade IV; : heterotopic ossification at latest followup: 0: none, 1: grade I, 2: grade II, and 3: grade III; : radiographic result: 1: no change, 2: trabecular incorporation, 3: trabecular remodeling, and 4: cortical healing.
